STX2

Across TCGA pan-cancer cohorts, STX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated STX2 data layer compared with 30 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STX2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and OV show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where STX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.235	0.526	.001	31	view →
HNSC	OS	Quartile	All	0.963	0.777	.011	12	view →
LSCC	DFS	Median	II,III,IV	0.836	1.000	.005	10	view →
LUAD	OS	Tertile	III,IV	0.676	1.000	.010	9	view →
OV	DFS	Median	All	1.000	0.622	.007	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

STX2–PDAC (DFS)

Open the PDAC breakdown →